Semin Liver Dis 2001; 21(1): 027-042
DOI: 10.1055/s-2001-12927
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Etiopathogenesis of Nonalcoholic Steatohepatitis

Shivakumar Chitturi, Geoffrey C. Farrell
  • Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia
Further Information

Publication History

Publication Date:
31 December 2001 (online)

ABSTRACT

The definable causes of nonalcoholic steatohepatitis (NASH) include jejunoileal bypass surgery (JIB), other causes of rapid and profound weight loss in obese subjects, total parenteral nutrition, drugs, industrial toxins, copper toxicity, and disorders characterized by extreme insulin resistance. However, the etiopathogenesis in most cases of NASH appears multifactorial. Obesity, type 2 diabetes, and hypertriglyceridemia are often associated with hepatic steatosis, and although this does not invariably lead to NASH, the fatty liver is vulnerable to hepatocellular injury initiated by reactive oxygen species (ROS). It is critical to understand not only the triggers for hepatitis (injury and inflammation) in NASH but also how this is perpetuated as chronic liver disease. The present focus is on whether the biochemical processes that generate oxidative stress lead to hepatocyte injury and secondary recruitment of inflammation or whether inflammation is the primary mediator of liver cell injury. Insulin resistance is a reproducible pathogenic factor in NASH. It favors accumulation of free fatty acids in the liver and predisposes to oxidative stress by stimulating microsomal lipid peroxidases and by the direct effects of high insulin levels in decreasing mitochondrial β-oxidation. CYP2E1 is normally suppressed by insulin but is invariably increased in the livers of patients with NASH. In rodent dietary models of steatohepatitis, CYP2E1 is the catalyst of microsomal lipid peroxidation, while in Cyp 2e1 nullizygous mice, CYP4A proteins are induced and function as alternative microsomal lipid peroxidases. Other studies implicate activation of peroxisome proliferator-activated receptor-α (PPARα) as leading to NASH; PPARα is a transcription factor that governs both microsomal (via CYP4A) and peroxisomal (β-oxidation) pathways of lipid oxidation and ultimately production of ROS. Increased lipid peroxidation is a crucial difference between the livers of rodents with experimental NASH and those of ob/ob genetically obese mice that have uncomplicated steatosis. Administration of endotoxin, through the release of tumor necrosis factor-α (TNF-α), provokes liver inflammation with hepatocyte injury in the steatotic liver. This may be particularly relevant in JIB and has been suggested as a pathogenic mechanism in primary NASH. It has been proposed that inheriting one or more copies of the hemochromatosis gene, C282Y, promotes fibrotic progression in NASH because of increased hepatic iron deposition, but recent studies have failed to confirm this. The relationship between the severity of hepatitis in NASH and progression to cirrhosis implies that products of the inflammatory infiltrate play a role in fibrogenesis. In summary, NASH can be regarded as the hepatic consequence of the metabolic syndrome (or syndrome X). Attention should now shift from steatosis, a generally benign process that is less evident in the advanced stages of cirrhosis, to the mechanisms for hepatocellular injury, inflammation, and hepatic fibrosis. In particular, the genetic, molecular, and cellular factors that ordain and moderate fibrosis in the context of steatohepatitis will be of greatest relevance to effective therapy and clinical outcome.

REFERENCES

  • 1 Ludwig J, Viggiano T R, McGill D B. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc . 1980;  55 434-438
  • 2 Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients.  Am J Med . 1979;  67 811-816
  • 3 Batman P A, Scheuer P J. Diabetic hepatitis preceding the onset of glucose intolerance.  Histopathology . 1985;  9 237-243
  • 4 Baldridge A D, Perez-Atayde A R, Graeme-Cook F. Idiopathic steatohepatitis in childhood: a multicentre retrospective study.  J Pediatr . 1995;  127 700
  • 5 Teli M R, James O F, Burt A D. The natural history of nonalcoholic fatty liver.  Hepatology . 1995;  22 1714-1719
  • 6 Caldwell S H, Oelsner D H, Iezzoni J C. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying liver disease.  Hepatology . 1999;  29 664-669
  • 7 Brunt E M, Janney C G, Di Bisceglie M A. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol . 1999;  94 2467-2474
  • 8 Koteish A, Diehl A M. Animal models of steatosis.  Semin Liver Dis . 2001;  21 89-104
  • 9 Pessayre S, Berson A, Fromenty B. Mitochondria in steatohepatitis.  Semin Liver Dis . 2001;  21 57-70
  • 10 Hocking M P, Davis G L, Franzini D A. Long-term consequences after jejunoileal bypass for morbid obesity.  Dig Dis Sci . 1998;  43 2493-2499
  • 11 Peters R L, Gay T, Reynolds T B. Post-jejunoileal bypass hepatic disease. Its similarity to alcoholic liver disease.  Am J Clin Pathol . 1975;  63 318-331
  • 12 Nazim M, Stamp G, Hodgson H J. Nonalcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth.  Hepatogastroenterology . 1989;  36 349-351
  • 13 Yost R L, Duerson M C, Russell W L. Doxycycline in the prevention of hepatic dysfunction: an evaluation of its use following jejunoileal bypass in humans.  Arch Surg . 1979;  114 931-934
  • 14 Tuma D J, Vanderhoof J A, Sorrell M F. Impaired hepatic drug metabolism after jejunoileal bypass in rats.  J Pharmacol Exp Ther . 1978;  206 167-171
  • 15 Vanderhoof J A, Metz M J, Tuma D J. Effect of improved absorption on development of jejunoileal bypass- induced liver dysfunction in rats.  Dig Dis Sci . 1980;  25 581-586
  • 16 Vanderhoof J A, Tuma D J, Antonson D L. Etiology of jejunoileal bypass-induced liver dysfunction in rats.  Dig Dis Sci . 1981;  26 328-333
  • 17 Whelan G, Wood B. The metabolic consequences of jejunoileal bypass for obesity.  Aust N Z J Surg . 1980;  50 520-524
  • 18 Baker H, Vanderhoof J A, Tuma D J. A jejunoileal bypass rat model for rapid study of the effects of vitamin malabsorption.  Int J Vitam Nutr Res . 1992;  62 43-46
  • 19 Halsted C H. Obesity: effects on the liver and gastrointestinal system.  Curr Opin Gastroenterol . 1999;  15 154-158
  • 20 Luyckx F H, Lefebvre P J, Scheen A J. Nonalcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.  Diabetes Metab . 2000;  26 98-106
  • 21 Peura D A, Stromeyer F W, Johnson L F. Liver injury with alcoholic hyaline after intestinal resection.  Gastroenterology . 1980;  79 128-130
  • 22 Acosta D, Wenzel D G. Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells.  Atherosclerosis . 1974;  20 417-426
  • 23 Hotamisligil G H, Spiegelman B M. Tumor necrosis factor-α. A key component of the obesity-diabetes link.  Diabetes . 1994;  43 1271-1278
  • 24 Yang S Q, Lin H Z, Lane M D. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis.  Proc Natl Acad Sci U S A . 1997;  94 2557-2562
  • 25 Chavin K D, Yang S, Lin H Z. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion.  J Biol Chem . 1999;  274 5692-5700
  • 26 Song B J, Matsunaga T, Hardwick J P. Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat.  Mol Endocrinol . 1987;  1 542-547
  • 27 Dong Z G, Hong J Y, Ma Q A. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats.  Arch Biochem Biophys . 1988;  263 29-35
  • 28 Wigg A J, Roberts-Thomson I C, Dymock R B. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumour necrosis factor alpha in the pathogenesis of nonalcoholic steatohepatitis.  Gut . 2001;  48 206-211
  • 29 Hu Y, Ingelman-Sunberg M, Lindros K O. Induction mechanisms of cytochrome P450 2E1 in liver: interplay between ethanol treatment and starvation.  Biochem Pharmacol . 1995;  17 155-161
  • 30 Quigley E M, Marsh M N, Shaffer J L. Hepatobiliary complications of total parenteral nutrition.  Gastroenterology . 1993;  104 286-301
  • 31 George D K, Goldwurm S, Macdonald G A. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.  Gastroenterology . 1998;  114 311-318
  • 32 Younossi Z M, Gramlich T, Bacon B R. Hepatic iron and nonalcoholic fatty liver disease.  Hepatology . 1999;  30 847-850
  • 33 Herion D W, Arioglu E, Doo E. Severe insulin resistance syndromes and nonalcoholic steatohepatitis. Proceedings of a Symposium on Nonalcoholic Steatohepatitis, National Institutes of Health, Bethesda, MD, 1998
  • 34 Angulo P, Lindor K D. Treatment of nonalcoholic fatty liver: present and emerging therapies.  Semin Liver Dis . 2001;  21 81-88
  • 35 Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients.  Gastroenterology . 1990;  99 1408-1413
  • 36 Cuellar R E, Tarter R, Hays A. The possible occurrence of `alcoholic hepatitis' in a patient with bulimia in the absence of diagnostic alcoholism.  Hepatology . 1987;  7 878-883
  • 37 Capron J-P, Delamarre J, Dupas J-L. Fasting in obesity. Another cause of liver injury with alcoholic hyaline?.  Dig Dis Sci . 1982;  27 265-268
  • 38 Bowyer B A, Fleming C R, Ludwig J. Does long-term home parenteral nutrition in adult patients cause chronic liver disease?.  JPEN J Parenter Enteral Nutr . 1985;  9 11-17
  • 39 Craig R M, Neumann T, Jeejeebhoy K N. Severe hepatocellular reaction resembling alcoholic hepatitis with cirrhosis after massive small bowel resection and prolonged total parenteral nutrition.  Gastroenterology . 1980;  79 131-137
  • 40 Lewis J H, Mullick F, Ishak K G. Histopathologic analysis of suspected amiodarone hepatotoxicity.  Hum Pathol . 1990;  21 59-67
  • 41 Farrell G C. Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone 1994
  • 42 Pirovino M, Müller O, Zysset T. Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model.  Hepatology . 1988;  8 591-598
  • 43 Lewis J H, Ranard R C, Caruso A. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients.  Hepatology . 1989;  9 679-685
  • 44 Simon J B, Manley P N, Brien J F. Amiodarone hepatotoxicity simulating alcoholic liver disease.  N Engl J Med . 1984;  311 167-172
  • 45 Pessayre D, Bichara M, Degott C. Perhexiline maleate-induced cirrhosis.  Gastroenterology . 1979;  76 170-177
  • 46 Seki K, Minami Y, Nishikawa M. Nonalcoholic steatohepatitis induced by massive doses of synthetic estrogen.  Gastroenterol Jpn . 1983;  18 197-203
  • 47 Cortez-Pinto H, Baptista A, Camilo M E. Tamoxifen-associated steatohepatitis-report of three cases.  J Hepatol . 1995;  23 95-97
  • 48 Ogawa Y, Murata Y, Nishioka A. Tamoxifen-induced fatty liver in patients with breast cancer.  Lancet . 1998;  351 725
  • 49 Pratt D S, Knox T A, Erban J. Tamoxifen-induced steatohepatitis (Letter).  Ann Intern Med . 1995;  123 236
  • 50 Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis (Letter).  Ann Intern Med . 1996;  124 855-856
  • 51 Oien K A, Moffat D, Curry G W. Cirrhosis with steatohepatitis after adjuvant tamoxifen (Letter).  Lancet . 1999;  353 36-37
  • 52 Saibara T, Ogawa Y, Takahashi M. Tamoxifen-induced nonalcoholic steatohepatitis and bezafibrate (Abstract).  J Gastroenterol Hepatol . 2000;  15(Suppl) F96
  • 53 Angulo P, Keach J C, Batts K P. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology . 1999;  30 1356-1362
  • 54 Beaugrand M, Denis J, Callard P. Tous les inhibiteurs calciques peuvent-ils entrainer des lésions d'hépatite alcoolique?.  Gastroenterol Clin Biol . 1987;  1 76
  • 55 Babany G, Uzzan F, Larrey D. Alcoholic-like liver lesions induced by nifedipine.  J Hepatol . 1989;  9 252-255
  • 56 Redlich C A, West A B, Fleming L. Clinical and pathologic characteristics associated with occupational exposure to dimethylformamide.  Gastroenterology . 1990;  99 748-757
  • 57 Cotrim H P, Andrade Z A, Parana R. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers.  Liver . 1999;  19 299-304
  • 58 Solis-Herruzo J A, Vidal J V, Colina F. Clinico-biochemical evolution and late hepatic lesions in the toxic oil syndrome.  Gastroenterology . 1987;  93 558-568
  • 59 Belfiore F, Iannello S. Insulin resistance in obesity: metabolic mechanisms and measurement methods.  Mol Genet Metab . 1998;  65 121-128
  • 60 Powell E E, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy.  Gastroenterology . 1989;  97 1022-1024
  • 61 Rashid M, Roberts E A. Nonalcoholic steatohepatitis in children.  J Pediatr Gastroenterol Nutr . 2000;  30 48-53
  • 62 Naschitz J E, Yeshurun D, Zuckerman E. Massive hepatic steatosis complicating adult celiac disease: report of a case and review of the literature.  Am J Gastroenterol . 1987;  82 1186-1189
  • 63 Angulo P, Jorgensen R A, Lindor K D. Prevalence of serum antiendomysial antibodies in patients with nonalcoholic steatohepatitis.  Gastroenterology . 1999;  116 1184A
  • 64 Partin J S, Partin J C, Schubert W K. Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis.  Gastroenterology . 1974;  67 107-118
  • 65 Illingworth D R, Connor W E, Miller R G. Abetalipoproteinemia: report of 2 cases and review of therapy.  Arch Neurol . 1980;  37 659-662
  • 66 Stromeyer F W, Ishak K G. Histology of the liver in Wilson's disease: a study of 34 cases.  Am J Clin Pathol . 1980;  73 12-24
  • 67 Baker A, Gormally S, Saxena R. Copper-associated liver disease in childhood.  J Hepatol . 1995;  23 538-543
  • 68 Bavdekar A R, Bhave S A, Pradhan A M. Long term survival in Indian childhood cirrhosis treated with D-penicillamine.  Arch Dis Child . 1996;  74 32-35
  • 69 Sheth S G, Gordon F D, Chopra S. Nonalcoholic steatohepatitis.  Ann Intern Med . 1997;  126 137-145
  • 70 Ludwig J, McGill D B, Lindor K D. Review: nonalcoholic steatohepatitis.  J Gastroenterol Hepatol . 1997;  12 398-403
  • 71 James O FW, Day C P. Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance.  J Hepatol . 1998;  29 495-501
  • 72 Bacon B R, Farahvash M J, Janney C G. Nonalcoholic steatohepatitis: an expanded clinical entity.  Gastroenterology . 1994;  107 1103-1109
  • 73 Lenaerts J, Verresen L, Van Steenbergen W. Fatty liver hepatitis and type 5 hyperlipoproteinemia in juvenile diabetes mellitus. Case report and review of the literature.  J Clin Gastroenterol . 1990;  12 93-97
  • 74 Falchuk K R, Fiske S C, Haggitt R C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus.  Gastroenterology . 1980;  78 535-541
  • 75 Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. In: Popper H, Schaffner F (eds) Progress in Liver Disease, Vol III. New York: Grune & Stratton, 1970: 331
  • 76 Mason A L, Lau J YN, Hoang N. Association of diabetes mellitus and chronic hepatitis C virus infection.  Hepatology . 1999;  29 328-333
  • 77 Petrides A S, Vogt C, Schulze-Berge D. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis.  Hepatology . 1994;  19 614-627
  • 78 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology . 1990;  12 1106-1110
  • 79 Kakkar R, Kalra J, Mantha S V. Lipid peroxidation and activity of antioxidant enzymes in diabetic rats.  Mol Cell Biochem . 1995;  151 113-119
  • 80 Powell E E, Edwards-Smith C J, Hay J L. Host genetic factors influence disease progression in chronic hepatitis C.  Hepatology . 2000;  31 828-833
  • 81 McClain C J, Barve S, Deaciuc I. Cytokines in alcoholic liver disease.  Semin Liver Dis . 1999;  19 205-219
  • 82 Hill D, Barve S, Joshi-Barve S. Increased monocyte nuclear factor-κB activation and tumor necrosis factor production on alcoholic hepatitis.  J Lab Clin Med . 2000;  135 387-395
  • 83 Farrell G C. Is bacterial ash the flash that ignites NASH (Editorial)?.  Gut . 2001;  48 148-149
  • 84 Andersen T, Gluud C. Liver morphology in morbid obesity: a literature study.  Int J Obes . 1984;  8 97-106
  • 85 Marceau P, Biron S, Hould F-S. Liver pathology and the metabolic syndrome X in severe obesity.  J Clin Endocrinol Metab . 1999;  84 1513-1517
  • 86 Ratziu V, Giral P, Charlotte F. Liver fibrosis in overweight patients.  Gastroenterology . 2000;  118 1117-1123
  • 87 Naveau S, Giraud V, Borotto E. Excess weight risk factor for alcoholic liver disease.  Hepatology . 1997;  25 108-111
  • 88 Hourigan L F, MacDonald G A, Purdie D. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis.  Hepatology . 1999;  29 1215-1219
  • 89 Cortez-Pinto H, Camilo M E, Baptista A. Non-alcoholic fatty liver: another feature of the metabolic syndrome?.  Clin Nutr . 1999;  18 353-835
  • 90 Fiatarone J R, Coverdale S A, Batey R G. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis.  J Gastroenterol Hepatol . 1991;  6 585-590
  • 91 Leclercq I A, Farrell G C, Field J. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis.  J Clin Invest . 2000;  105 1067-1075
  • 92 Struben V MD, Hespenheide E E, Caldwell S H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med .  2000;  108 9-13
  • 93 Chitturi S, Fung C, Farrell G C. Prevalence of haemochromatosis gene mutations in nonalcoholic steatohepatitis (Abstract).  J Gastroenterol Hepatol (in press).
  • 94 Khan M H, Farrell G C, Blyth K. Which patients with hepatitis C develop liver complications?.  Hepatology . 2000;  31 513-520
  • 95 Chitturi S, Fung C, Farrell G C. Clinical and biochemical predictors of advanced fibrosis in NASH (Abstract).  Hepatology . 2000;  32 535A
  • 96 Houglum K, Ramm G A, Crawford D H. Excess iron induces hepatic oxidative stress and transforming growth factor-β1 in genetic hemochromatosis.  Hepatology . 1997;  26 605-610
  • 97 Bonkovsky H L, Banner B F, Lambrecht R W. Iron in liver diseases other than hemochromatosis.  Semin Liver Dis . 1996;  16 65-82
  • 98 Deugnier Y, Turlin B, le Quilleuc D. A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis.  Am J Surg Pathol . 1997;  21 669-675
  • 99 Bode C, Gast J, Zelder O. Alcohol-induced liver injury after jejunoileal bypass operation in rats.  J Hepatol . 1987;  5 75-84
  • 100 Whiting-O'Keefe Q E, Fyfe K H, Sack K D. Methotrexate and histologic hepatic abnormalities: a meta-analysis.  Am J Med . 1991;  90 711-716
  • 101 Fong D G, Nehra V, Lindor K D. Metabolic and nutritional considerations in nonalcoholic fatty liver.  Hepatology . 2000;  32 3-10
  • 102 Hashimoto T, Fujita T, Usuda N. Peroxisomal and mitochondrial fatty acid β-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor α and peroxisomal fatty acyl-CoA oxidase.  J Biol Chem . 1999;  274 19228-19236
  • 103 Fan C-Y, Pan J, Usuda N. Steatohepatitis, spontaneous peroxisomal proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisomal proliferator-activated receptor α natural ligand metabolism.  J Biol Chem . 1998;  273 15639-15645
  • 104 Marchesini G, Brizi M, Morselli-Labate A M. Association of nonalcoholic fatty liver disease with insulin resistance.  Am J Med . 1999;  107 450-455
  • 105 Guebre-Xabier M, Yang S Q, Lin H Z. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage.  Hepatology . 2000;  31 633-640
  • 106 McCullough A J, Bugianesi E, Marchesini G. Gender-dependent alterations in serum leptin in alcoholic cirrhosis.  Gastroenterology . 1998;  115 947-953
  • 107 Shimizu H, Kakizaki S, Tsuchiya T. An increase of circulating leptin levels in patients with liver cirrhosis.  Int J Obes Relat Metab Disord . 1998;  22 1234-1238
  • 108 Weltman M D, Leclerq I, Farrell G C. Hepatocyte cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis.  Hepatology . 1998;  27 128-133
  • 109 Raucy J L, Lasker J M, Kraner J C. Induction of cytochrome P450IIE1 in the obese overfed rat.  Mol Pharmacol . 1991;  39 275-280
  • 110 Ekström G, Ingelman-Sundberg M. Rat-liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450(P-450 IIE1).  Biochem Pharmacol . 1989;  38 1313-1319
  • 111 Nanji A A, Zhao S, Sadrzadeh S M. Marked enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats.  Alcohol Clin Exp Res . 1994;  18 1280-1285
  • 112 Weltman M D, Farrell G C, Liddle C. Increased hepatocyte CYP 2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.  Gastroenterology . 1996;  111 1645-1653
  • 113 Kirsch R, Shephard E, Kirsch R. The rat nutritional model of nonalcoholic steatohepatitis: strain and gender studies (Abstract).  J Gastroenterol Hepatol . 2000;  15(Suppl) F81
  • 114 Leclercq I, Field J, Enriquez A. Constitutive and inducible expression of hepatic CYP2E1 and CYP4A in leptin-deficient ob/ob mice.  Biochem Biophys Res Commun . 2000;  268 337-344
  • 115 Kono H, Bradford B U, Yin M. CYP2E1 is not involved in early alcohol-induced liver injury.  Am J Physiol . 1999;  277 G1259-1267
  • 116 Wan Y-J, Cai J, Li J. Regulation of peroxisome proliferator activated receptor α mediated pathways in alcohol fed cytochrome P450 deficient mice (Abstract).  J Gastroenterol Hepatol . 2000;  15(Suppl) F90
  • 117 Enriquez A, Leclercq I, Farrell G C. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice and fa/fa Zucker rats.  Biochem Biophys Res Commun . 1999;  255 300-306
  • 118 Zhang C, Walker L M, Hinson J A. Oxidant stress in rat liver after lipopolysaccharide administration: effect of inducible nitric-oxide synthase inhibition.  J Pharmacol Exp Ther . 2000;  293 968-972
  • 119 Fernandez-Checa J C, Kaplowitz N, Garcia-Ruiz C. Mitochondrial glutathione: importance and transport.  Semin Liver Dis . 1998;  18 389-401
  • 120 Yang S Q, Zhu H, Li Y B. Mitochondrial adaptations to obesity-related oxidant stress.  Arch Biochem Biophys . 2000;  378 259-268
  • 121 Matteoni C A, Younossi Z M, Gramlich T. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology . 1999;  116 1413-1419
  • 122 Crespo J, Amado J A, Garcia-Unzueta M T. Leptin and TNF alpha levels in hepatitis C and its relationship with hepatic fibrosis (Abstract).  J Hepatol . 2000;  32(Suppl 2) 65
  • 123 Merli M, Valeriano V, Masini A. Leptin in cirrhotic patients (Abstract).  J Hepatol . 2000;  32(Suppl 2) 213
  • 124 Potter J J, Womack L, Mezey E. Transdifferentiation of rat hepatic stellate cells results in leptin expression.  Biochem Biophys Res Commun . 1998;  244 178-182